Interestingly, when considering all cancers, there is a significant difference in overall survival among these TP53 interface-defined tumour subtypes, with variants at the zinc binding site being associated with poorer overall survival (logrank, p = 3,12e−3; Fig. 5d) as well as compared to mutually exclusive TP53 mutations perturbing alternative interfaces (i.e. TP53BP1; Fig. 5c, Table S2c). This evidence concerns the gene TP53 and cancer.